Annual Cash & Cash Equivalents
$25.66 M
+$7.07 M+38.02%
31 December 2023
Summary:
Galectin Therapeutics annual cash & cash equivalents is currently $25.66 million, with the most recent change of +$7.07 million (+38.02%) on 31 December 2023. During the last 3 years, it has fallen by -$1.48 million (-5.46%). GALT annual cash & cash equivalents is now -45.96% below its all-time high of $47.48 million, reached on 31 December 2019.GALT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$27.06 M
+$1.46 M+5.71%
30 September 2024
Summary:
Galectin Therapeutics quarterly cash and cash equivalents is currently $27.06 million, with the most recent change of +$1.46 million (+5.71%) on 30 September 2024. Over the past year, it has increased by +$6.70 million (+32.89%). GALT quarterly cash and cash equivalents is now -48.00% below its all-time high of $52.04 million, reached on 30 June 2019.GALT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +38.0% | +32.9% |
| 3 y3 years | -5.5% | -26.1% |
| 5 y5 years | +210.9% | -46.2% |
GALT Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -35.3% | +38.0% | -31.8% | +70.9% |
| 5 y | 5 years | -46.0% | +210.9% | -46.2% | +70.9% |
| alltime | all time | -46.0% | >+9999.0% | -48.0% | >+9999.0% |
Galectin Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $27.06 M(+5.7%) |
| June 2024 | - | $25.60 M(+8.7%) |
| Mar 2024 | - | $23.55 M(-8.2%) |
| Dec 2023 | $25.66 M(+38.0%) | $25.66 M(+26.0%) |
| Sept 2023 | - | $20.36 M(+13.3%) |
| June 2023 | - | $17.97 M(+0.9%) |
| Mar 2023 | - | $17.80 M(-4.3%) |
| Dec 2022 | $18.59 M(-53.1%) | $18.59 M(+17.4%) |
| Sept 2022 | - | $15.83 M(-34.5%) |
| June 2022 | - | $24.18 M(-23.5%) |
| Mar 2022 | - | $31.61 M(-20.3%) |
| Dec 2021 | $39.65 M(+46.1%) | $39.65 M(+8.3%) |
| Sept 2021 | - | $36.60 M(+15.8%) |
| June 2021 | - | $31.60 M(+52.2%) |
| Mar 2021 | - | $20.76 M(-23.5%) |
| Dec 2020 | $27.14 M(-42.8%) | $27.14 M(-16.6%) |
| Sept 2020 | - | $32.56 M(-20.1%) |
| June 2020 | - | $40.77 M(-5.9%) |
| Mar 2020 | - | $43.33 M(-8.7%) |
| Dec 2019 | $47.48 M(+475.3%) | $47.48 M(-5.7%) |
| Sept 2019 | - | $50.34 M(-3.3%) |
| June 2019 | - | $52.04 M(+646.5%) |
| Mar 2019 | - | $6.97 M(-15.5%) |
| Dec 2018 | $8.25 M(+170.3%) | $8.25 M(-18.6%) |
| Sept 2018 | - | $10.14 M(-3.4%) |
| June 2018 | - | $10.50 M(+163.2%) |
| Mar 2018 | - | $3.99 M(+30.6%) |
| Dec 2017 | $3.05 M(-80.1%) | $3.05 M(-56.1%) |
| Sept 2017 | - | $6.96 M(-23.8%) |
| June 2017 | - | $9.13 M(-33.1%) |
| Mar 2017 | - | $13.64 M(-11.2%) |
| Dec 2016 | $15.36 M(-40.6%) | $15.36 M(-4.3%) |
| Sept 2016 | - | $16.06 M(-10.8%) |
| June 2016 | - | $18.00 M(-19.5%) |
| Mar 2016 | - | $22.36 M(-13.5%) |
| Dec 2015 | $25.85 M(-11.3%) | $25.85 M(+21.2%) |
| Sept 2015 | - | $21.32 M(-19.1%) |
| June 2015 | - | $26.36 M(-10.2%) |
| Mar 2015 | - | $29.35 M(+0.8%) |
| Dec 2014 | $29.13 M(+177.7%) | $29.13 M(-6.6%) |
| Sept 2014 | - | $31.20 M(-9.4%) |
| June 2014 | - | $34.42 M(-5.9%) |
| Mar 2014 | - | $36.59 M(+248.9%) |
| Dec 2013 | $10.49 M(+12.0%) | $10.49 M(+8.0%) |
| Sept 2013 | - | $9.71 M(+90.5%) |
| June 2013 | - | $5.10 M(-27.3%) |
| Mar 2013 | - | $7.02 M(-25.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $9.36 M(+46.4%) | $9.36 M(-15.3%) |
| Sept 2012 | - | $11.06 M(-15.8%) |
| June 2012 | - | $13.13 M(-14.3%) |
| Mar 2012 | - | $15.31 M(+139.4%) |
| Dec 2011 | $6.40 M(+8.6%) | $6.40 M(-19.5%) |
| Sept 2011 | - | $7.94 M(-0.5%) |
| June 2011 | - | $7.98 M(+14.9%) |
| Mar 2011 | - | $6.95 M(+17.9%) |
| Dec 2010 | $5.89 M(+2247.0%) | $5.89 M(+109.3%) |
| Sept 2010 | - | $2.81 M(-1.7%) |
| June 2010 | - | $2.86 M(+2285.8%) |
| Mar 2010 | - | $120.00 K(-52.2%) |
| Dec 2009 | $251.00 K(-21.1%) | $251.00 K(-46.4%) |
| Sept 2009 | - | $468.00 K(-52.3%) |
| June 2009 | - | $982.00 K(+14.1%) |
| Mar 2009 | - | $861.00 K(+170.8%) |
| Dec 2008 | $318.00 K(-75.9%) | $318.00 K(-61.0%) |
| Sept 2008 | - | $816.00 K(-47.5%) |
| June 2008 | - | $1.55 M(-52.3%) |
| Mar 2008 | - | $3.25 M(+146.8%) |
| Dec 2007 | $1.32 M(+70.6%) | $1.32 M(+15.9%) |
| Sept 2007 | - | $1.14 M(-52.2%) |
| June 2007 | - | $2.38 M(-44.9%) |
| Mar 2007 | - | $4.32 M(+459.2%) |
| Dec 2006 | $773.00 K(-82.7%) | $773.00 K(-75.3%) |
| Sept 2006 | - | $3.13 M(-33.8%) |
| June 2006 | - | $4.72 M(-60.3%) |
| Mar 2006 | - | $11.89 M(+166.3%) |
| Dec 2005 | $4.47 M(-58.3%) | $4.47 M(-25.6%) |
| Sept 2005 | - | $6.00 M(-18.2%) |
| June 2005 | - | $7.34 M(-19.2%) |
| Mar 2005 | - | $9.08 M(-15.2%) |
| Dec 2004 | $10.70 M(+40.7%) | $10.70 M(-14.1%) |
| Sept 2004 | - | $12.45 M(+41.9%) |
| June 2004 | - | $8.78 M(+34.1%) |
| Mar 2004 | - | $6.54 M(-14.0%) |
| Dec 2003 | $7.61 M(+296.0%) | $7.61 M(+58.9%) |
| Sept 2003 | - | $4.79 M(+167.3%) |
| June 2003 | - | $1.79 M(-16.7%) |
| Mar 2003 | - | $2.15 M(+11.9%) |
| Dec 2002 | $1.92 M(+28.8%) | $1.92 M(+50.6%) |
| Sept 2002 | - | $1.28 M(+61.7%) |
| June 2002 | - | $789.00 K(-18.4%) |
| Mar 2002 | - | $967.40 K(-35.1%) |
| Dec 2001 | $1.49 M | $1.49 M(+72.2%) |
| Sept 2001 | - | $865.90 K(+16.0%) |
| June 2001 | - | $746.40 K |
FAQ
- What is Galectin Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Galectin Therapeutics?
- What is Galectin Therapeutics annual cash & cash equivalents year-on-year change?
- What is Galectin Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Galectin Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of GALT is $25.66 M
What is the all time high annual cash & cash equivalents for Galectin Therapeutics?
Galectin Therapeutics all-time high annual cash & cash equivalents is $47.48 M
What is Galectin Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, GALT annual cash & cash equivalents has changed by +$7.07 M (+38.02%)
What is Galectin Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GALT is $27.06 M
What is the all time high quarterly cash and cash equivalents for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly cash and cash equivalents is $52.04 M
What is Galectin Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, GALT quarterly cash and cash equivalents has changed by +$6.70 M (+32.89%)